| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Microglia | 12 | 2023 | 166 | 5.290 |
Why?
|
| Antineoplastic Agents, Phytogenic | 9 | 2021 | 110 | 4.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 17 | 2023 | 807 | 4.060 |
Why?
|
| Cell Line, Tumor | 43 | 2024 | 2231 | 3.660 |
Why?
|
| Plant Extracts | 8 | 2024 | 286 | 3.580 |
Why?
|
| Benzoquinones | 7 | 2022 | 36 | 3.460 |
Why?
|
| Anti-Inflammatory Agents | 10 | 2023 | 149 | 3.430 |
Why?
|
| Tumor Necrosis Factor-alpha | 11 | 2023 | 356 | 3.390 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 10 | 2021 | 30 | 3.210 |
Why?
|
| Cell Proliferation | 19 | 2023 | 1198 | 3.090 |
Why?
|
| Chemokine CCL2 | 7 | 2022 | 85 | 2.970 |
Why?
|
| Cell Survival | 34 | 2021 | 864 | 2.920 |
Why?
|
| Antineoplastic Agents | 10 | 2022 | 803 | 2.870 |
Why?
|
| Hydrolyzable Tannins | 4 | 2021 | 16 | 2.680 |
Why?
|
| NF-kappa B | 6 | 2023 | 339 | 2.670 |
Why?
|
| Apoptosis | 19 | 2024 | 1398 | 2.650 |
Why?
|
| Flavonoids | 5 | 2022 | 87 | 2.520 |
Why?
|
| Lipopolysaccharides | 14 | 2023 | 220 | 2.500 |
Why?
|
| Antioxidants | 11 | 2024 | 416 | 2.440 |
Why?
|
| Biological Products | 4 | 2023 | 71 | 2.340 |
Why?
|
| Vitis | 3 | 2024 | 31 | 2.160 |
Why?
|
| Neuroprotective Agents | 5 | 2022 | 245 | 2.150 |
Why?
|
| L-Lactate Dehydrogenase | 4 | 2021 | 62 | 2.090 |
Why?
|
| Breast Neoplasms | 8 | 2024 | 1502 | 2.070 |
Why?
|
| Lactic Acid | 7 | 2021 | 95 | 2.060 |
Why?
|
| Glioma | 8 | 2016 | 79 | 2.050 |
Why?
|
| Cytokines | 8 | 2021 | 602 | 1.870 |
Why?
|
| Humans | 71 | 2024 | 37093 | 1.870 |
Why?
|
| Naphthoquinones | 3 | 2018 | 36 | 1.830 |
Why?
|
| Allyl Compounds | 6 | 2024 | 47 | 1.770 |
Why?
|
| Monoamine Oxidase | 5 | 2020 | 34 | 1.650 |
Why?
|
| Cytostatic Agents | 2 | 2021 | 7 | 1.600 |
Why?
|
| Glycolysis | 8 | 2021 | 68 | 1.580 |
Why?
|
| MAP Kinase Signaling System | 4 | 2022 | 169 | 1.550 |
Why?
|
| Apigenin | 3 | 2019 | 13 | 1.540 |
Why?
|
| Neoplasm Proteins | 4 | 2021 | 213 | 1.520 |
Why?
|
| Cell Cycle | 7 | 2021 | 326 | 1.440 |
Why?
|
| High-Throughput Screening Assays | 4 | 2021 | 65 | 1.440 |
Why?
|
| Gossypol | 2 | 2020 | 5 | 1.420 |
Why?
|
| Gene Expression | 4 | 2022 | 674 | 1.330 |
Why?
|
| Hydrogen Peroxide | 9 | 2022 | 190 | 1.320 |
Why?
|
| Sulfides | 5 | 2024 | 62 | 1.310 |
Why?
|
| Gene Expression Profiling | 8 | 2021 | 626 | 1.310 |
Why?
|
| NF-E2-Related Factor 2 | 4 | 2023 | 77 | 1.300 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2020 | 25 | 1.300 |
Why?
|
| Mitochondria | 9 | 2014 | 487 | 1.290 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 123 | 1.250 |
Why?
|
| Animals | 49 | 2024 | 15081 | 1.250 |
Why?
|
| Interferon-gamma | 7 | 2018 | 250 | 1.230 |
Why?
|
| Hydroxamic Acids | 2 | 2018 | 32 | 1.210 |
Why?
|
| Neuroblastoma | 11 | 2012 | 129 | 1.200 |
Why?
|
| Reactive Oxygen Species | 7 | 2024 | 461 | 1.200 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2018 | 37 | 1.190 |
Why?
|
| Gene Expression Regulation | 6 | 2020 | 1015 | 1.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 88 | 1.190 |
Why?
|
| Signal Transduction | 11 | 2023 | 1908 | 1.160 |
Why?
|
| Xanthophylls | 2 | 2023 | 15 | 1.160 |
Why?
|
| Mice | 24 | 2024 | 5913 | 1.140 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2020 | 1039 | 1.090 |
Why?
|
| Epigenesis, Genetic | 4 | 2022 | 219 | 1.090 |
Why?
|
| Glutathione | 8 | 2022 | 179 | 1.080 |
Why?
|
| Glucose | 7 | 2020 | 230 | 1.060 |
Why?
|
| Isoquinolines | 2 | 2022 | 45 | 0.990 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2023 | 269 | 0.980 |
Why?
|
| Brain Neoplasms | 4 | 2015 | 111 | 0.980 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2020 | 147 | 0.970 |
Why?
|
| 3T3-L1 Cells | 1 | 2024 | 16 | 0.970 |
Why?
|
| Anti-Obesity Agents | 1 | 2024 | 10 | 0.970 |
Why?
|
| Neoplasms | 3 | 2022 | 1103 | 0.960 |
Why?
|
| Cell Line | 11 | 2023 | 1354 | 0.960 |
Why?
|
| Adipocytes | 1 | 2024 | 58 | 0.930 |
Why?
|
| Paclitaxel | 2 | 2021 | 50 | 0.930 |
Why?
|
| MicroRNAs | 2 | 2021 | 426 | 0.910 |
Why?
|
| Female | 25 | 2024 | 20969 | 0.900 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 131 | 0.900 |
Why?
|
| Seaweed | 1 | 2022 | 11 | 0.870 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2020 | 90 | 0.860 |
Why?
|
| Breast | 2 | 2021 | 135 | 0.860 |
Why?
|
| Nitric Oxide Synthase | 4 | 2005 | 128 | 0.860 |
Why?
|
| Hesperidin | 1 | 2022 | 5 | 0.850 |
Why?
|
| Citrus | 1 | 2022 | 15 | 0.840 |
Why?
|
| Inflammation | 5 | 2023 | 618 | 0.820 |
Why?
|
| Environment | 2 | 2014 | 138 | 0.820 |
Why?
|
| Dioscorea | 1 | 2021 | 3 | 0.820 |
Why?
|
| Thiophenes | 1 | 2021 | 31 | 0.800 |
Why?
|
| Prostatic Neoplasms | 4 | 2020 | 935 | 0.800 |
Why?
|
| Pyridones | 1 | 2021 | 40 | 0.790 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 35 | 0.780 |
Why?
|
| Phytotherapy | 1 | 2021 | 81 | 0.780 |
Why?
|
| I-kappa B Kinase | 2 | 2022 | 44 | 0.780 |
Why?
|
| Chemokine CXCL1 | 1 | 2021 | 15 | 0.770 |
Why?
|
| Benzamides | 2 | 2021 | 78 | 0.770 |
Why?
|
| Iridoids | 1 | 2020 | 5 | 0.760 |
Why?
|
| Rats | 22 | 2019 | 3483 | 0.760 |
Why?
|
| Tetrahydroisoquinolines | 2 | 2021 | 21 | 0.760 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2020 | 5 | 0.750 |
Why?
|
| Depsides | 1 | 2020 | 3 | 0.750 |
Why?
|
| Cataract | 1 | 2020 | 26 | 0.750 |
Why?
|
| Cinnamates | 1 | 2020 | 6 | 0.750 |
Why?
|
| Reishi | 1 | 2020 | 6 | 0.730 |
Why?
|
| Interleukin-8 | 1 | 2020 | 60 | 0.720 |
Why?
|
| Herbicides | 3 | 2010 | 44 | 0.720 |
Why?
|
| Neurons | 5 | 2015 | 1175 | 0.700 |
Why?
|
| Chalcones | 1 | 2019 | 14 | 0.700 |
Why?
|
| Contraceptive Agents, Male | 1 | 2019 | 3 | 0.690 |
Why?
|
| Plants, Medicinal | 2 | 2010 | 68 | 0.680 |
Why?
|
| Nitric Oxide | 7 | 2023 | 316 | 0.680 |
Why?
|
| Epithelial Cells | 2 | 2024 | 384 | 0.670 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 186 | 0.660 |
Why?
|
| Nitric Oxide Synthase Type II | 8 | 2017 | 115 | 0.660 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 24 | 0.640 |
Why?
|
| Dopamine | 7 | 2006 | 245 | 0.630 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 251 | 0.620 |
Why?
|
| Boswellia | 1 | 2017 | 2 | 0.620 |
Why?
|
| Interleukin-1alpha | 2 | 2017 | 18 | 0.620 |
Why?
|
| Triterpenes | 1 | 2017 | 14 | 0.610 |
Why?
|
| Imidazoles | 1 | 2018 | 126 | 0.610 |
Why?
|
| Cell Line, Transformed | 4 | 2020 | 91 | 0.610 |
Why?
|
| Models, Biological | 4 | 2021 | 677 | 0.600 |
Why?
|
| Melanoma | 1 | 2018 | 96 | 0.590 |
Why?
|
| Psoralea | 1 | 2017 | 2 | 0.590 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 11 | 0.580 |
Why?
|
| Nitrogen Dioxide | 1 | 2016 | 10 | 0.580 |
Why?
|
| Nerve Growth Factor | 2 | 2015 | 30 | 0.580 |
Why?
|
| Seeds | 1 | 2017 | 35 | 0.570 |
Why?
|
| Genistein | 1 | 2017 | 42 | 0.570 |
Why?
|
| Up-Regulation | 4 | 2022 | 513 | 0.560 |
Why?
|
| RNA, Messenger | 6 | 2022 | 1207 | 0.560 |
Why?
|
| Momordica | 2 | 2019 | 14 | 0.550 |
Why?
|
| Oxadiazoles | 1 | 2016 | 15 | 0.550 |
Why?
|
| Gene Silencing | 1 | 2017 | 151 | 0.550 |
Why?
|
| Tumor Cells, Cultured | 9 | 2019 | 502 | 0.540 |
Why?
|
| Obesity | 1 | 2024 | 1067 | 0.540 |
Why?
|
| Sepsis | 1 | 2016 | 80 | 0.530 |
Why?
|
| Microtubules | 1 | 2016 | 120 | 0.520 |
Why?
|
| Silymarin | 1 | 2015 | 2 | 0.520 |
Why?
|
| Genes, p53 | 1 | 2015 | 25 | 0.510 |
Why?
|
| Isoenzymes | 3 | 2021 | 161 | 0.500 |
Why?
|
| Garlic | 3 | 2024 | 30 | 0.500 |
Why?
|
| Phencyclidine | 2 | 2006 | 19 | 0.500 |
Why?
|
| Drug Design | 1 | 2016 | 162 | 0.500 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 54 | 0.500 |
Why?
|
| Neurotoxins | 3 | 2020 | 57 | 0.490 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 409 | 0.490 |
Why?
|
| Neurogenesis | 1 | 2015 | 58 | 0.490 |
Why?
|
| Down-Regulation | 3 | 2022 | 435 | 0.490 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 905 | 0.490 |
Why?
|
| Astrocytes | 3 | 2021 | 255 | 0.480 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2014 | 39 | 0.480 |
Why?
|
| Escherichia coli | 1 | 2016 | 453 | 0.460 |
Why?
|
| Depression | 1 | 2020 | 712 | 0.460 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 352 | 0.450 |
Why?
|
| Pyruvic Acid | 2 | 2003 | 18 | 0.450 |
Why?
|
| Cell Differentiation | 3 | 2024 | 587 | 0.450 |
Why?
|
| Ecosystem | 1 | 2014 | 123 | 0.440 |
Why?
|
| Precancerous Conditions | 2 | 2024 | 82 | 0.440 |
Why?
|
| Macrophages | 1 | 2016 | 439 | 0.440 |
Why?
|
| TNF Receptor-Associated Factor 2 | 2 | 2023 | 16 | 0.440 |
Why?
|
| Carotenoids | 2 | 2023 | 70 | 0.440 |
Why?
|
| Neuroglia | 2 | 2005 | 124 | 0.440 |
Why?
|
| Oxidative Phosphorylation | 2 | 2010 | 53 | 0.420 |
Why?
|
| Ascorbic Acid | 1 | 2012 | 66 | 0.410 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2022 | 36 | 0.400 |
Why?
|
| Ibuprofen | 2 | 2016 | 32 | 0.390 |
Why?
|
| Kidney Neoplasms | 2 | 2022 | 68 | 0.390 |
Why?
|
| Lysophosphatidylcholines | 3 | 2005 | 22 | 0.380 |
Why?
|
| Parkinson Disease | 2 | 2011 | 178 | 0.380 |
Why?
|
| Repressor Proteins | 3 | 2022 | 249 | 0.370 |
Why?
|
| Fruit | 2 | 2024 | 173 | 0.370 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2017 | 113 | 0.370 |
Why?
|
| Homeostasis | 1 | 2012 | 188 | 0.370 |
Why?
|
| Kinetics | 5 | 2020 | 708 | 0.360 |
Why?
|
| Oxidative Stress | 5 | 2024 | 938 | 0.360 |
Why?
|
| Caspase 3 | 2 | 2023 | 207 | 0.360 |
Why?
|
| Manganese | 2 | 2021 | 87 | 0.360 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 358 | 0.360 |
Why?
|
| Cytoprotection | 3 | 2009 | 36 | 0.360 |
Why?
|
| Acids | 1 | 2009 | 18 | 0.350 |
Why?
|
| Cell Movement | 3 | 2022 | 571 | 0.340 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 2019 | 421 | 0.340 |
Why?
|
| Mercury Poisoning | 1 | 2009 | 5 | 0.340 |
Why?
|
| PC12 Cells | 6 | 2019 | 93 | 0.340 |
Why?
|
| MPTP Poisoning | 2 | 2006 | 11 | 0.330 |
Why?
|
| Oxidopamine | 2 | 2005 | 20 | 0.300 |
Why?
|
| Molecular Structure | 4 | 2017 | 492 | 0.300 |
Why?
|
| Nitrites | 4 | 2015 | 46 | 0.300 |
Why?
|
| Manganese Poisoning | 2 | 2020 | 22 | 0.290 |
Why?
|
| Dopamine Agents | 1 | 2007 | 25 | 0.290 |
Why?
|
| Histone Deacetylases | 2 | 2018 | 56 | 0.290 |
Why?
|
| Blotting, Western | 5 | 2012 | 859 | 0.290 |
Why?
|
| Structure-Activity Relationship | 2 | 2020 | 409 | 0.290 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2006 | 99 | 0.280 |
Why?
|
| Phosphatidylethanolamine N-Methyltransferase | 2 | 2005 | 6 | 0.280 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2020 | 19 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 448 | 0.270 |
Why?
|
| Lysine | 2 | 2017 | 113 | 0.270 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2020 | 306 | 0.260 |
Why?
|
| Phospholipids | 2 | 2005 | 70 | 0.260 |
Why?
|
| Oxidation-Reduction | 5 | 2004 | 431 | 0.260 |
Why?
|
| Motor Activity | 4 | 2006 | 418 | 0.260 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2006 | 137 | 0.260 |
Why?
|
| Adenosine Triphosphate | 3 | 2017 | 196 | 0.260 |
Why?
|
| Neurotransmitter Agents | 2 | 2020 | 63 | 0.250 |
Why?
|
| Superoxides | 3 | 2016 | 53 | 0.250 |
Why?
|
| Analysis of Variance | 4 | 2017 | 550 | 0.250 |
Why?
|
| Gliosis | 1 | 2004 | 24 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 222 | 0.250 |
Why?
|
| Minority Groups | 2 | 2021 | 596 | 0.250 |
Why?
|
| Smoke | 1 | 2005 | 40 | 0.250 |
Why?
|
| Proteomics | 2 | 2019 | 325 | 0.250 |
Why?
|
| Nerve Degeneration | 1 | 2004 | 107 | 0.240 |
Why?
|
| p120 GTPase Activating Protein | 1 | 2023 | 3 | 0.240 |
Why?
|
| Ubiquinone | 1 | 2004 | 22 | 0.240 |
Why?
|
| Benzo(a)pyrene | 2 | 2024 | 126 | 0.240 |
Why?
|
| Mutation | 2 | 2022 | 1095 | 0.230 |
Why?
|
| DNA Damage | 3 | 2024 | 352 | 0.230 |
Why?
|
| Acetylcarnitine | 1 | 2003 | 8 | 0.230 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2023 | 6 | 0.230 |
Why?
|
| Anticarcinogenic Agents | 1 | 2024 | 65 | 0.230 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2004 | 73 | 0.230 |
Why?
|
| Protective Agents | 1 | 2003 | 25 | 0.220 |
Why?
|
| Hydroxydopamines | 1 | 2003 | 4 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 152 | 0.220 |
Why?
|
| Gluconeogenesis | 1 | 2003 | 10 | 0.220 |
Why?
|
| NAD | 1 | 2003 | 50 | 0.220 |
Why?
|
| Antiparkinson Agents | 1 | 2002 | 12 | 0.220 |
Why?
|
| Corpus Striatum | 2 | 2004 | 104 | 0.220 |
Why?
|
| Levodopa | 1 | 2002 | 20 | 0.220 |
Why?
|
| Models, Molecular | 2 | 2017 | 808 | 0.220 |
Why?
|
| Benzophenanthridines | 1 | 2022 | 9 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 161 | 0.210 |
Why?
|
| Chemokines | 1 | 2023 | 97 | 0.210 |
Why?
|
| Chlorides | 2 | 2013 | 56 | 0.210 |
Why?
|
| Phenols | 2 | 2021 | 80 | 0.210 |
Why?
|
| Catechin | 1 | 2022 | 31 | 0.200 |
Why?
|
| DNA Polymerase beta | 1 | 2021 | 13 | 0.200 |
Why?
|
| Bromodeoxyuridine | 1 | 2021 | 24 | 0.200 |
Why?
|
| Breast Feeding | 1 | 2023 | 113 | 0.200 |
Why?
|
| Autophagy | 1 | 2022 | 116 | 0.200 |
Why?
|
| DNA Repair | 2 | 2024 | 188 | 0.190 |
Why?
|
| Vimentin | 1 | 2021 | 37 | 0.190 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2021 | 38 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 122 | 0.190 |
Why?
|
| S-Adenosylmethionine | 4 | 2005 | 38 | 0.190 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 120 | 0.190 |
Why?
|
| Antigens, CD | 1 | 2021 | 121 | 0.190 |
Why?
|
| Cadherins | 1 | 2021 | 90 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 121 | 0.190 |
Why?
|
| Cation Transport Proteins | 1 | 2020 | 34 | 0.190 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2020 | 3 | 0.190 |
Why?
|
| Osteoprotegerin | 1 | 2020 | 10 | 0.190 |
Why?
|
| Acetylcysteine | 2 | 2013 | 62 | 0.190 |
Why?
|
| Superoxide Dismutase | 2 | 2016 | 155 | 0.180 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 51 | 0.180 |
Why?
|
| Drug Discovery | 1 | 2021 | 82 | 0.180 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2020 | 83 | 0.180 |
Why?
|
| Cyclotides | 1 | 2019 | 4 | 0.180 |
Why?
|
| Catalytic Domain | 1 | 2020 | 109 | 0.180 |
Why?
|
| Protein Array Analysis | 2 | 2017 | 25 | 0.180 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2012 | 364 | 0.170 |
Why?
|
| Brain | 3 | 2020 | 1346 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 1 | 2021 | 197 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2020 | 239 | 0.170 |
Why?
|
| Research | 1 | 2021 | 163 | 0.170 |
Why?
|
| Nerve Growth Factors | 1 | 2019 | 33 | 0.170 |
Why?
|
| Behavioral Research | 1 | 2019 | 39 | 0.160 |
Why?
|
| Male | 12 | 2022 | 20025 | 0.160 |
Why?
|
| Anaerobiosis | 2 | 2009 | 15 | 0.160 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2013 | 133 | 0.160 |
Why?
|
| Binding, Competitive | 2 | 2017 | 111 | 0.160 |
Why?
|
| Minority Health | 1 | 2019 | 88 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 229 | 0.160 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 433 | 0.160 |
Why?
|
| Smoking | 1 | 2005 | 940 | 0.150 |
Why?
|
| Cell Respiration | 2 | 2010 | 35 | 0.150 |
Why?
|
| Disaster Planning | 1 | 2018 | 52 | 0.150 |
Why?
|
| Petroselinum | 1 | 2017 | 4 | 0.150 |
Why?
|
| Quality of Life | 1 | 2022 | 481 | 0.150 |
Why?
|
| Aerobiosis | 2 | 2009 | 15 | 0.150 |
Why?
|
| Disasters | 1 | 2018 | 65 | 0.150 |
Why?
|
| Cyclonic Storms | 1 | 2018 | 64 | 0.150 |
Why?
|
| Central Nervous System Stimulants | 1 | 2019 | 174 | 0.150 |
Why?
|
| Methamphetamine | 1 | 2019 | 159 | 0.150 |
Why?
|
| Aging | 1 | 2022 | 664 | 0.140 |
Why?
|
| Protein Binding | 4 | 2019 | 972 | 0.140 |
Why?
|
| Lipid Peroxides | 1 | 2016 | 17 | 0.140 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 25 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2020 | 517 | 0.140 |
Why?
|
| Molecular Conformation | 1 | 2017 | 152 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 112 | 0.140 |
Why?
|
| Drug Synergism | 2 | 2015 | 177 | 0.140 |
Why?
|
| Catalase | 1 | 2016 | 109 | 0.140 |
Why?
|
| Tubulin | 1 | 2016 | 88 | 0.140 |
Why?
|
| Neutrophils | 1 | 2016 | 131 | 0.130 |
Why?
|
| Enzyme Activation | 1 | 2017 | 444 | 0.130 |
Why?
|
| Hela Cells | 1 | 2017 | 366 | 0.130 |
Why?
|
| Manganese Compounds | 2 | 2013 | 16 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 448 | 0.130 |
Why?
|
| Dacarbazine | 1 | 2015 | 6 | 0.130 |
Why?
|
| Etoposide | 1 | 2015 | 22 | 0.130 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2015 | 32 | 0.130 |
Why?
|
| Universities | 1 | 2018 | 442 | 0.130 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 93 | 0.120 |
Why?
|
| Drug Interactions | 2 | 2006 | 141 | 0.120 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 83 | 0.120 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2014 | 32 | 0.120 |
Why?
|
| Hepatocytes | 1 | 2014 | 75 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 400 | 0.120 |
Why?
|
| Oxidants | 2 | 2005 | 45 | 0.120 |
Why?
|
| Disulfides | 1 | 2014 | 77 | 0.120 |
Why?
|
| Oxygen Consumption | 2 | 2004 | 103 | 0.110 |
Why?
|
| Prostate | 1 | 2015 | 154 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2014 | 80 | 0.110 |
Why?
|
| Behavior, Animal | 2 | 2006 | 314 | 0.110 |
Why?
|
| Methylation | 4 | 2006 | 113 | 0.110 |
Why?
|
| DNA Breaks, Single-Stranded | 1 | 2013 | 13 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2014 | 118 | 0.110 |
Why?
|
| Glutamic Acid | 2 | 2021 | 128 | 0.110 |
Why?
|
| Proteome | 1 | 2014 | 144 | 0.110 |
Why?
|
| Estradiol | 1 | 2014 | 262 | 0.100 |
Why?
|
| DNA Fingerprinting | 1 | 2012 | 18 | 0.100 |
Why?
|
| Heterochromatin | 1 | 2012 | 16 | 0.100 |
Why?
|
| Nucleosomes | 1 | 2012 | 29 | 0.100 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 78 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 103 | 0.100 |
Why?
|
| Liliaceae | 1 | 2010 | 2 | 0.100 |
Why?
|
| Boraginaceae | 1 | 2010 | 2 | 0.100 |
Why?
|
| Apiaceae | 1 | 2010 | 3 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2015 | 1518 | 0.100 |
Why?
|
| Melanins | 1 | 2011 | 36 | 0.090 |
Why?
|
| Middle Aged | 2 | 2022 | 10129 | 0.090 |
Why?
|
| Histones | 1 | 2012 | 190 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 58 | 0.090 |
Why?
|
| Vitamins | 1 | 2011 | 94 | 0.090 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2010 | 84 | 0.090 |
Why?
|
| Alcohols | 1 | 2009 | 12 | 0.090 |
Why?
|
| Fermentation | 1 | 2009 | 26 | 0.090 |
Why?
|
| Ketones | 1 | 2009 | 17 | 0.090 |
Why?
|
| Mercuric Chloride | 1 | 2009 | 2 | 0.090 |
Why?
|
| Buthionine Sulfoximine | 1 | 2009 | 12 | 0.090 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2009 | 17 | 0.090 |
Why?
|
| Florida | 2 | 2023 | 410 | 0.080 |
Why?
|
| Aldehydes | 1 | 2009 | 69 | 0.080 |
Why?
|
| Prognosis | 2 | 2022 | 739 | 0.080 |
Why?
|
| Tritium | 2 | 2006 | 51 | 0.080 |
Why?
|
| Transcription, Genetic | 2 | 2021 | 578 | 0.080 |
Why?
|
| Dizocilpine Maleate | 2 | 2006 | 48 | 0.080 |
Why?
|
| Sulfhydryl Compounds | 1 | 2009 | 47 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2005 | 1618 | 0.080 |
Why?
|
| Amino Acids | 1 | 2009 | 145 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2012 | 325 | 0.080 |
Why?
|
| S-Adenosylhomocysteine | 2 | 2005 | 9 | 0.080 |
Why?
|
| Pyridinium Compounds | 2 | 2005 | 27 | 0.080 |
Why?
|
| Dopamine Antagonists | 2 | 2004 | 44 | 0.070 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 2 | 2006 | 13 | 0.070 |
Why?
|
| Fluorescein | 1 | 2007 | 16 | 0.070 |
Why?
|
| Luminescence | 1 | 2007 | 24 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2007 | 143 | 0.070 |
Why?
|
| Membrane Potentials | 1 | 2007 | 223 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2022 | 681 | 0.070 |
Why?
|
| Biogenic Amines | 1 | 2006 | 11 | 0.070 |
Why?
|
| Paraquat | 1 | 2006 | 21 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 181 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 252 | 0.070 |
Why?
|
| N-Methylaspartate | 1 | 2006 | 57 | 0.070 |
Why?
|
| Neurites | 1 | 2006 | 39 | 0.070 |
Why?
|
| Receptors, Dopamine D1 | 2 | 2004 | 40 | 0.070 |
Why?
|
| Phosphatidylethanolamines | 1 | 2005 | 27 | 0.070 |
Why?
|
| Homocysteine | 1 | 2005 | 19 | 0.070 |
Why?
|
| Phosphatidylcholines | 1 | 2005 | 47 | 0.060 |
Why?
|
| Sympatholytics | 1 | 2005 | 14 | 0.060 |
Why?
|
| Annexin A5 | 1 | 2004 | 26 | 0.060 |
Why?
|
| Propidium | 1 | 2004 | 19 | 0.060 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2004 | 22 | 0.060 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2005 | 35 | 0.060 |
Why?
|
| G2 Phase | 1 | 2004 | 29 | 0.060 |
Why?
|
| Tyrosine | 1 | 2005 | 118 | 0.060 |
Why?
|
| Electron Transport Complex III | 1 | 2004 | 13 | 0.060 |
Why?
|
| Receptors, Dopamine | 1 | 2004 | 25 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2004 | 98 | 0.060 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2024 | 51 | 0.060 |
Why?
|
| Phosphoenolpyruvate | 1 | 2003 | 4 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 95 | 0.060 |
Why?
|
| Ataxia | 1 | 2003 | 9 | 0.060 |
Why?
|
| Stereotyped Behavior | 1 | 2003 | 22 | 0.060 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2023 | 36 | 0.060 |
Why?
|
| Catechols | 1 | 2002 | 5 | 0.060 |
Why?
|
| Monosaccharides | 1 | 2003 | 11 | 0.060 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2002 | 9 | 0.050 |
Why?
|
| Imines | 1 | 2002 | 10 | 0.050 |
Why?
|
| Caspases | 1 | 2023 | 147 | 0.050 |
Why?
|
| Free Radicals | 1 | 2002 | 74 | 0.050 |
Why?
|
| Methionine | 1 | 2002 | 30 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2002 | 52 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 211 | 0.050 |
Why?
|
| Zinc Fingers | 1 | 2022 | 26 | 0.050 |
Why?
|
| Parkinsonian Disorders | 1 | 2002 | 37 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2003 | 343 | 0.050 |
Why?
|
| Caco-2 Cells | 1 | 2021 | 52 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 49 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 105 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 360 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 1742 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 515 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 53 | 0.050 |
Why?
|
| Databases, Genetic | 1 | 2021 | 93 | 0.050 |
Why?
|
| Mothers | 1 | 2023 | 181 | 0.050 |
Why?
|
| Transferrin | 1 | 2020 | 40 | 0.050 |
Why?
|
| DNA | 1 | 2024 | 574 | 0.050 |
Why?
|
| Survival Rate | 1 | 2021 | 311 | 0.050 |
Why?
|
| alpha-Synuclein | 1 | 2020 | 52 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2020 | 76 | 0.050 |
Why?
|
| Brain Chemistry | 3 | 2005 | 140 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2023 | 894 | 0.050 |
Why?
|
| Biomimetics | 1 | 2019 | 10 | 0.040 |
Why?
|
| Infant | 1 | 2023 | 1046 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2019 | 38 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 730 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 515 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2019 | 140 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 80 | 0.040 |
Why?
|
| New Orleans | 1 | 2018 | 13 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2020 | 305 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2019 | 389 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2019 | 133 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 155 | 0.040 |
Why?
|
| Pregnancy | 1 | 2003 | 1549 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 169 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2019 | 362 | 0.040 |
Why?
|
| Texas | 1 | 2018 | 324 | 0.040 |
Why?
|
| Aged | 2 | 2021 | 6741 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 104 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 2379 | 0.030 |
Why?
|
| Child | 1 | 2023 | 3131 | 0.030 |
Why?
|
| Injections, Intraventricular | 2 | 2005 | 64 | 0.030 |
Why?
|
| Adipokines | 1 | 2014 | 24 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 560 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2018 | 1378 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2014 | 153 | 0.030 |
Why?
|
| Thymine | 1 | 2013 | 25 | 0.030 |
Why?
|
| Comet Assay | 1 | 2013 | 76 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2013 | 81 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 642 | 0.030 |
Why?
|
| Heme Oxygenase-1 | 1 | 2012 | 51 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1130 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 399 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4268 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2006 | 1609 | 0.020 |
Why?
|
| United States | 1 | 2019 | 4223 | 0.020 |
Why?
|
| Homovanillic Acid | 1 | 2006 | 10 | 0.020 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 2006 | 27 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 11712 | 0.020 |
Why?
|
| Catheterization | 1 | 2005 | 24 | 0.020 |
Why?
|
| Neostriatum | 1 | 2005 | 26 | 0.020 |
Why?
|
| Hypokinesia | 1 | 2005 | 3 | 0.020 |
Why?
|
| Quinacrine | 1 | 2005 | 5 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2005 | 44 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2005 | 78 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 2005 | 37 | 0.020 |
Why?
|
| Adenosine | 1 | 2005 | 59 | 0.020 |
Why?
|
| Mazindol | 1 | 2004 | 4 | 0.020 |
Why?
|
| Methyltransferases | 1 | 2005 | 58 | 0.020 |
Why?
|
| Serotonin | 1 | 2005 | 123 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 2004 | 66 | 0.010 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2004 | 50 | 0.010 |
Why?
|
| Benzazepines | 1 | 2004 | 32 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 207 | 0.010 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2004 | 77 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 893 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2002 | 26 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 46 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2002 | 77 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2002 | 92 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 78 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 381 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 479 | 0.010 |
Why?
|
| Proteins | 1 | 2002 | 369 | 0.010 |
Why?
|